{"success":true,"data":{"pressRelease":{"id":"159598","rtpr_id":"nGNEcfw9Mx-20261002","ticker":"CATX","exchange":"NYSE American","all_tickers":["CATX"],"title":"Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026","author":"Globe Newswire","published_at":"2026-10-02T15:46:00.230Z","article_body":"SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.\n(“Perspective,” the “Company,” “we,” “us,” and “our”)\n(NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering\nadvanced treatments for cancers throughout the body, today announced that data\nfrom the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01)\nprogram have been accepted for presentation at the Society for Immunotherapy\nof Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place\nNovember 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further\ndetails for regular abstracts on November 3, 2026.\n\n Presenting Author                                   Abstract Title                                                                                                                                                                                Presentation Details                                                                                                                                    \n Matthew Block, Department of Oncology, Mayo Clinic  A phase I/IIa trial of [ (212)Pb]VMT01 MC1R-targeted alpha-particle mono- and combination-therapy with nivolumab in participants with previously treated unresectable or metastatic melanoma  Abstract Number: 571 Presentation type: Poster presentation Date: Friday, Nov. 6, 2026 Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6  \n\nAbout [²¹²Pb]VMT-01\n\nPerspective designed [(212)Pb]VMT01 to target and deliver (212)Pb to\nmetastatic melanoma tumor sites expressing MC1R, a protein that can be\noverexpressed in metastatic melanoma tumors.(1) The Company is conducting a\nmulti-center, open-label dose escalation, dose expansion study\n(clinicaltrials.gov identifier NCT05655312\n(https://www.globenewswire.com/Tracker?data=R-wQ08eeEQDaXtKRtaygrxQDin9DtLnIXD__fmf8kTbiSqedJjCEwdgudBE2sTd1x7-23z_8aNe1LPoBvDWqSebRvkR2S2wZVhbJelAtUZwJerPmQmUG96fUfH5PEotX))\nin patients with histologically confirmed melanoma and MC1R-positive imaging\nscans.\n\nInterim analysis with a data cut-off date of March 25, 2026 was presented at\nthe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May\n2026\n(https://www.globenewswire.com/Tracker?data=Ga3XM4jmpvNpfsgBZtHpa1VhcITzlbhqv-mvs0K3IVl7vWl5_e5d-D0DtsjTksMlN2MW1G1Y6WfVG0Zupq9ylNqWB0Ik6C2sn456ec5YU48cw-oc8mPyPFNvNFLARdn0ShxEmGv4cIIjFnJTAWREbhuOoWTTZLzJYBJrOFalMxoA6NBr0g1dHZlkTY9WY1LqZo8dmzSo6oNYbrBnqp_povT8-UJZ7x3XBrqf9I-H3QDefqMGeBZPAVFLZqvkWA-XT0NBl5sV2VQycNmwtarYp9VIocg1xC5OE5yzFCMV5VA=).\nHighlights from the ASCO analysis included the following:\n* Patients were heavily pre-treated prior to entering trial with a median of 4\nprior lines of systemic therapy (including prior checkpoint inhibitors)\n\n\n* One new response was observed early in the 3.0 mCi monotherapy cohort, in\naddition to a previously reported response, for a total of two responders out\nof seven treated patients\n\n\n* Six patients (86%) experienced stable disease or partial response out of the\nseven patients in the 3.0 mCi monotherapy cohort; four patients completed all\nthree treatments with 24 weeks or more of follow-up since their first\ntreatment, and two remained on treatment and in study\n* [²¹²Pb]VMT01 was well-tolerated with no dose limiting toxicities (DLTs),\nno discontinuations due to adverse events, and no Grade 4 or Grade 5 treatment\nemergent adverse events (TEAEs)\n* Eight (30%) patients out of a total of 27 patients treated experienced Grade\n3 TEAEs\nAbout Perspective Therapeutics, Inc.\n\nPerspective Therapeutics, Inc. is a radiopharmaceutical development company\npioneering advanced treatments for cancers throughout the body. The Company\nhas proprietary technology that utilizes the alpha-generating isotope (212)Pb\nto deliver powerful radiation specifically to cancer cells via specialized\ntargeting moieties. The Company is also developing complementary imaging\ntechniques that incorporate the same targeting moieties, which provides the\nopportunity to personalize treatment and optimize patient outcomes. This\n\"theranostic\" approach enables visualization of the specific tumor and\nsubsequent treatment, potentially improving efficacy and minimizing toxicity.\n\nThe Company is advancing a portfolio of clinical-stage programs in the U.S.,\nincluding bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors),\nlapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).\n\nThe Company is expanding its regional finished drug product candidate supply\nnetwork, enabled by its proprietary (224)Ra/(212)Pb generator platform used\nto manufacture clinical drug product candidates, to support the delivery of\npatient-ready drug product candidates for clinical trials and, if approved,\ncommercial operations.\n\nFor more information, please visit the Company's website\nat www.perspectivetherapeutics.com.\n\nSafe Harbor Statement\n\nThis press release contains forward-looking statements within the meaning of\nthe United States Private Securities Litigation Reform Act of 1995. Statements\nin this press release that are not statements of historical fact are\nforward-looking statements. Words such as \"may,\" \"will,\" \"should,\" \"expect,\"\n\"plan,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\" \"project,\" \"estimate,\"\n\"believe,\" \"predict,\" \"potential,\" or \"continue\" or the negative of these\nterms or other similar expressions are intended to identify forward-looking\nstatements, though not all forward-looking statements contain these\nidentifying words. Forward-looking statements in this press release include\nstatements concerning, among other things, the Company’s clinical\ndevelopment plans and the expected timing for the release of additional data\nfrom its clinical programs; the Company’s regional distribution and\nmanufacturing capabilities; and other statements that are not historical fact.\n\nThe Company may not actually achieve the plans, intentions, or expectations\ndisclosed in the forward-looking statements, and you should not place undue\nreliance on the forward-looking statements. These forward-looking statements\ninvolve risks and uncertainties that could cause the Company's actual results\nto differ materially from the results described in or implied by the\nforward-looking statements. Known risk factors include that the Company’s\npreclinical development plans and clinical trials may be more costly or take\nlonger to complete than anticipated, or may never be completed, or may not\ngenerate results that warrant future development of the tested product\ncandidate; the Company may elect to change its strategy regarding its product\ncandidates and development activities; economic and market conditions may\nworsen; regulatory agencies may issue decisions that negatively impact the\nCompany’s product candidates and clinical development plans; and risks\nrelated to the sufficiency of the Company’s cash resources for its future\noperating expenses and capital expenditures. A more complete discussion of the\nrisks and uncertainties facing the Company appears under the heading “Risk\nFactors” in the Company’s most recent Annual Report on Form 10-K filed\nwith the Securities and Exchange Commission (the “SEC”), in the\nCompany’s other filings with the SEC, and in the Company’s future reports\nto be filed with the SEC and available at www.sec.gov. Forward-looking\nstatements contained in this news release are made as of this date. Unless\nrequired to do so by law, we undertake no obligation to publicly update or\nrevise any forward-looking statements, whether as a result of new information,\nfuture events, or otherwise.\n\nMedia and Investor Relations Contacts:\n\nPerspective Therapeutics IR:\nAnnie J. Cheng, CFA\nir@perspectivetherapeutics.com\n\nENTENTE Network of Companies\nKatie Morris, PhD\nkatiemorris@ententeinc.com\n\n(1) Su DG, Djureinovic D, Schoenfeld D, et al. Melanocortin-1 Receptor\nExpression as a Marker of Progression in Melanoma. JCO Precis Oncol.\n2024;8:e2300702. doi:10.1200/PO.23.00702.","article_body_html":"","raw_payload":{"data":{"id":"nGNEcfw9Mx-20261002","title":"Perspective Therapeutics Announces Acceptance of [212Pb]VMT01 Data for Presentation at SITC 2026","author":"Globe Newswire","ticker":"CATX","created":"2026-10-02T15:46:00.230Z","tickers":["CATX"],"exchange":"NYSE American","article_body":"SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc.\n(“Perspective,” the “Company,” “we,” “us,” and “our”)\n(NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering\nadvanced treatments for cancers throughout the body, today announced that data\nfrom the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01)\nprogram have been accepted for presentation at the Society for Immunotherapy\nof Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place\nNovember 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further\ndetails for regular abstracts on November 3, 2026.\n\n Presenting Author                                   Abstract Title                                                                                                                                                                                Presentation Details                                                                                                                                    \n Matthew Block, Department of Oncology, Mayo Clinic  A phase I/IIa trial of [ (212)Pb]VMT01 MC1R-targeted alpha-particle mono- and combination-therapy with nivolumab in participants with previously treated unresectable or metastatic melanoma  Abstract Number: 571 Presentation type: Poster presentation Date: Friday, Nov. 6, 2026 Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6  \n\nAbout [²¹²Pb]VMT-01\n\nPerspective designed [(212)Pb]VMT01 to target and deliver (212)Pb to\nmetastatic melanoma tumor sites expressing MC1R, a protein that can be\noverexpressed in metastatic melanoma tumors.(1) The Company is conducting a\nmulti-center, open-label dose escalation, dose expansion study\n(clinicaltrials.gov identifier NCT05655312\n(https://www.globenewswire.com/Tracker?data=R-wQ08eeEQDaXtKRtaygrxQDin9DtLnIXD__fmf8kTbiSqedJjCEwdgudBE2sTd1x7-23z_8aNe1LPoBvDWqSebRvkR2S2wZVhbJelAtUZwJerPmQmUG96fUfH5PEotX))\nin patients with histologically confirmed melanoma and MC1R-positive imaging\nscans.\n\nInterim analysis with a data cut-off date of March 25, 2026 was presented at\nthe 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May\n2026\n(https://www.globenewswire.com/Tracker?data=Ga3XM4jmpvNpfsgBZtHpa1VhcITzlbhqv-mvs0K3IVl7vWl5_e5d-D0DtsjTksMlN2MW1G1Y6WfVG0Zupq9ylNqWB0Ik6C2sn456ec5YU48cw-oc8mPyPFNvNFLARdn0ShxEmGv4cIIjFnJTAWREbhuOoWTTZLzJYBJrOFalMxoA6NBr0g1dHZlkTY9WY1LqZo8dmzSo6oNYbrBnqp_povT8-UJZ7x3XBrqf9I-H3QDefqMGeBZPAVFLZqvkWA-XT0NBl5sV2VQycNmwtarYp9VIocg1xC5OE5yzFCMV5VA=).\nHighlights from the ASCO analysis included the following:\n* Patients were heavily pre-treated prior to entering trial with a median of 4\nprior lines of systemic therapy (including prior checkpoint inhibitors)\n\n\n* One new response was observed early in the 3.0 mCi monotherapy cohort, in\naddition to a previously reported response, for a total of two responders out\nof seven treated patients\n\n\n* Six patients (86%) experienced stable disease or partial response out of the\nseven patients in the 3.0 mCi monotherapy cohort; four patients completed all\nthree treatments with 24 weeks or more of follow-up since their first\ntreatment, and two remained on treatment and in study\n* [²¹²Pb]VMT01 was well-tolerated with no dose limiting toxicities (DLTs),\nno discontinuations due to adverse events, and no Grade 4 or Grade 5 treatment\nemergent adverse events (TEAEs)\n* Eight (30%) patients out of a total of 27 patients treated experienced Grade\n3 TEAEs\nAbout Perspective Therapeutics, Inc.\n\nPerspective Therapeutics, Inc. is a radiopharmaceutical development company\npioneering advanced treatments for cancers throughout the body. The Company\nhas proprietary technology that utilizes the alpha-generating isotope (212)Pb\nto deliver powerful radiation specifically to cancer cells via specialized\ntargeting moieties. The Company is also developing complementary imaging\ntechniques that incorporate the same targeting moieties, which provides the\nopportunity to personalize treatment and optimize patient outcomes. This\n\"theranostic\" approach enables visualization of the specific tumor and\nsubsequent treatment, potentially improving efficacy and minimizing toxicity.\n\nThe Company is advancing a portfolio of clinical-stage programs in the U.S.,\nincluding bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors),\nlapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).\n\nThe Company is expanding its regional finished drug product candidate supply\nnetwork, enabled by its proprietary (224)Ra/(212)Pb generator platform used\nto manufacture clinical drug product candidates, to support the delivery of\npatient-ready drug product candidates for clinical trials and, if approved,\ncommercial operations.\n\nFor more information, please visit the Company's website\nat www.perspectivetherapeutics.com.\n\nSafe Harbor Statement\n\nThis press release contains forward-looking statements within the meaning of\nthe United States Private Securities Litigation Reform Act of 1995. Statements\nin this press release that are not statements of historical fact are\nforward-looking statements. Words such as \"may,\" \"will,\" \"should,\" \"expect,\"\n\"plan,\" \"anticipate,\" \"could,\" \"intend,\" \"target,\" \"project,\" \"estimate,\"\n\"believe,\" \"predict,\" \"potential,\" or \"continue\" or the negative of these\nterms or other similar expressions are intended to identify forward-looking\nstatements, though not all forward-looking statements contain these\nidentifying words. Forward-looking statements in this press release include\nstatements concerning, among other things, the Company’s clinical\ndevelopment plans and the expected timing for the release of additional data\nfrom its clinical programs; the Company’s regional distribution and\nmanufacturing capabilities; and other statements that are not historical fact.\n\nThe Company may not actually achieve the plans, intentions, or expectations\ndisclosed in the forward-looking statements, and you should not place undue\nreliance on the forward-looking statements. These forward-looking statements\ninvolve risks and uncertainties that could cause the Company's actual results\nto differ materially from the results described in or implied by the\nforward-looking statements. Known risk factors include that the Company’s\npreclinical development plans and clinical trials may be more costly or take\nlonger to complete than anticipated, or may never be completed, or may not\ngenerate results that warrant future development of the tested product\ncandidate; the Company may elect to change its strategy regarding its product\ncandidates and development activities; economic and market conditions may\nworsen; regulatory agencies may issue decisions that negatively impact the\nCompany’s product candidates and clinical development plans; and risks\nrelated to the sufficiency of the Company’s cash resources for its future\noperating expenses and capital expenditures. A more complete discussion of the\nrisks and uncertainties facing the Company appears under the heading “Risk\nFactors” in the Company’s most recent Annual Report on Form 10-K filed\nwith the Securities and Exchange Commission (the “SEC”), in the\nCompany’s other filings with the SEC, and in the Company’s future reports\nto be filed with the SEC and available at www.sec.gov. Forward-looking\nstatements contained in this news release are made as of this date. Unless\nrequired to do so by law, we undertake no obligation to publicly update or\nrevise any forward-looking statements, whether as a result of new information,\nfuture events, or otherwise.\n\nMedia and Investor Relations Contacts:\n\nPerspective Therapeutics IR:\nAnnie J. Cheng, CFA\nir@perspectivetherapeutics.com\n\nENTENTE Network of Companies\nKatie Morris, PhD\nkatiemorris@ententeinc.com\n\n(1) Su DG, Djureinovic D, Schoenfeld D, et al. Melanocortin-1 Receptor\nExpression as a Marker of Progression in Melanoma. JCO Precis Oncol.\n2024;8:e2300702. doi:10.1200/PO.23.00702."},"type":"article","timestamp":"2026-10-02T15:46:00.309088033Z","server_sent_at_ms":1790955960309},"received_at":"2026-10-02T15:46:00.360Z","source_url":null},"analysis":null,"durationMs":null,"modelName":null}}